AbbVie, Elahere and Ovarian Cancer
AbbVie’s Elahere wins European approval for certain ovarian cancers
GlobalData market analysts predict that Elahere could generate up to $1.98bn in revenue for AbbVie by 2030. Credit: Skorzewiak via Shutterstock. The European Commission (EC) has granted marketing authorisation to AbbVie’s Elahere (mirvetuximab ...
AbbVie Gets European OK of Elahere in Platinum-Resistant Ovarian Cancer
Elahere, which won initial U.S. Food and Drug Administration approval in 2022 for platinum-resistant ovarian cancer and full approval earlier this year, was the key asset in AbbVie's $10.1 billion acquisition of biotech ImmunoGen that closed in February.
AbbVie's $10.1 billion takeover of ImmunoGen has been rewarded with EU approval for Elahere, the first drug specifically ...
AbbVie (ABBV) announced that the European Commission approved ELAHERE or mirvetuximab soravtansine for the treatment of adult ...
Hosted on MSN7mon
Elahere secures full approval from FDA for types of ovarian cancerAbbVie’s monoclonal antibody Elahere (mirvetuximab soravtansine-gynx) has bagged full approval from the US Food and Drug Administration (FDA) for the treatment of certain types of ovarian cancer.
Discover how AbbVie investors that bought the anxiety over the loss of Humira exclusivity are sitting on massive gains. Read ...
ImmunoGen, Inc. has announced that its platinum-resistant ovarian cancer drug ELAHERE (mirvetuximab soravtansine-gynx) has been granted FDA accelerated approval. This first FDA antibody-drug ...
In the first quarter, AbbVie acquired ImmunoGen and its flagship cancer therapy, ELAHERE. This acquisition will allow ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback